Cargando…
Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
Chronic myeloid leukemia (CML) has a markedly improved prognosis with the use of breakpoint cluster region-abelson 1 (BCR-ABL1) tyrosine kinase inhibitors (BCR-ABL1 TKIs). However, approximately 40% of patients are resistant or intolerant to BCR-ABL1 TKIs. Hypoxia-inducible factor 1α (HIF-1α) is a h...
Autores principales: | Tsubaki, Masanobu, Takeda, Tomoya, Matsuda, Takuya, Kimura, Akihiro, Tanaka, Remi, Nagayoshi, Sakiko, Hoshida, Tadafumi, Tanabe, Kazufumi, Nishida, Shozo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978365/ https://www.ncbi.nlm.nih.gov/pubmed/36195570 http://dx.doi.org/10.5483/BMBRep.2022-0095 |
Ejemplares similares
-
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2017) -
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012) -
Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017) -
Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010) -
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)